In melanomas harboring the BRAF V600E/K mutation, the combined use of the BRAF inhibitor PLX4720 and the MEK inhibitor PD0325901 promotes GSDM-E cleavage and the release of HMGB1, along with an upregulation of IL-1β and IL-18, leading to pyroptosis induction [58]. Here, GSDME is linked to melanoma.